RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines

SIMPLE SUMMARY: To overcome some limitations of platinum-based chemotherapy agents, new active metallodrugs based on other transition metals are being researched. Runat-BI is a ruthenium-based compound which was synthesized and characterized at the University of Valencia. We investigated the in vitr...

Descripción completa

Detalles Bibliográficos
Autores principales: Albanell-Fernández, Marta, Oltra, Sara S., Orts-Arroyo, Marta, Ibarrola-Villava, Maider, Carrasco, Fany, Jiménez-Martí, Elena, Cervantes, Andrés, Castro, Isabel, Martínez-Lillo, José, Ribas, Gloria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817854/
https://www.ncbi.nlm.nih.gov/pubmed/36612065
http://dx.doi.org/10.3390/cancers15010069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817854/
https://www.ncbi.nlm.nih.gov/pubmed/36612065
http://dx.doi.org/10.3390/cancers15010069

Ejemplares similares